APM News and Press, Aptorum Group Limited From 05/06/21

Aptorum Group (APM) has entered into an agreement with Exeltis to develop, manufacture and commercialize a novel preclinical candidate intended to target woman’s health and gynecological conditions.The deal will help develop a preclinical candidate for Aptorum in the European Unio...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis (“Exeltis”) (a division of the global pharmaceut...

Regulatory News: Aptorum Group Limited (Nasdaq: APM), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced an interview with President and Executive Director, Mr. Darren Lui, will air on The RedChip ...

Aptorum Group (APM) is up 6% premarket after announcing material transfer and option agreement with Yale University for the preclinical stage development of its novel immunomodulators, potentially targeting autoimmune and oncology diseases.Under the arrangement, Aptorum will be...

Teradata Corporation (TDC) +28% on strong prelims results.Renalytix AI plc (RNLX) +22% on 10-year U.S. contract for KidneyIntelX testing.Qualtrics International (XM) +15% after profit surprise and strong guidance.Skillz (SKLZ) +13% as ARK Invest added additional shares.Gre...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement (“Agreementȁ...

Aptorum Group (APM): FY GAAP EPS of $0.20 beats by $0.80.Revenue of $0.91M (+68.5% Y/Y) beats by $0.21M.Press Release For further details see: Aptorum Group EPS beats by $0.80, beats on revenue

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on cli...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced dosing the first human subject in...

Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group (MARA) -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain (RIOT) -11% as Bitcoin crumbles despite good news rolls in.Foresight Autonomous (...